Fig. 1.

Genetic aberrations across common oncogenic pathways in CRC. Japanese patients (a) and US patients (b) were evaluated for gene alterations in the key cancer pathways. Amplification (red), deletion (blue), missense point mutations (green), or frameshift mutations (brown). Altered cases are defined as the total number of unique samples with a genetic aberration in each pathway. c Percent of patients with a variation for each given gene. Statistical significance was determined using Fisher’s exact test. d J-CRC, US-CRC, and TCGA sample data were evaluated for gene alterations in the dsDNA break repair pathway in the 415-gene panel. e Percent of patients with a variation for each given gene. Statistical significance was determined using Fisher’s exact test